Purpose:To assess usefulness and tolerability of switching glaucoma patients to the fixed combination Travoprost 0.004%/Timolol 0.5% with polyquad (PQ-TTFC); to record effects on tear film break-up time (TF-BUT) and on quality of life (OSDI). Methods:Multicenter, observational cohort, 6 month study. 50 patients on concomitant Timolol 0.5% (twice a day) and Dorzolamide (twice a day) or Timolol and Latanoptost (once a day) (BAK-preserved) were switched to PQ-TTFC (evening dosage). IOP, TFBUT and AEs were recorded and all patients completed the OSDI questionnaire at baseline and after 6 months. All analysis refers to right eye; left eye’s data are similar. Results:Median age was 70 [63-73] years, women were 54.9% of the sample. IOP significantly decreased (from 18 [16-21] to 15 [12-17] mmHg) after substitution (p<0,001). At baseline 31.4% of patients presented an IOP <18mmHg, the percentage increased to 80% of subjects at 6 months (p<0.001). TF-BUT improved of 2.7±1.9 sec (from 7 [5-8] to 10 [9-11] sec, p<0.001). Only one patient discontinued the new therapy due to periocular skin pigmentation. Quality of life improved from 28 (moderate) to 19 (mild) (p<0.001). Conclusions:PQ-TTFC appeared useful in this selected population: patients who underwent a regimen modification to PQ-TTFC obtained further reduction in IOP; improvement in ocular surface status with no exposition to BAK toxicity; and reported a better quality of life perception. The low discontinuation’s rate at 6 months indicates a good tolerability profile.

Six months study on signs and symptoms of polyquad preserved travoprost/timolol fixed combination on previously treated glaucoma patients.

ROLLE, Teresa;PENNA, Rachele Roberta;DALLORTO, LAURA;
2014

Abstract

Purpose:To assess usefulness and tolerability of switching glaucoma patients to the fixed combination Travoprost 0.004%/Timolol 0.5% with polyquad (PQ-TTFC); to record effects on tear film break-up time (TF-BUT) and on quality of life (OSDI). Methods:Multicenter, observational cohort, 6 month study. 50 patients on concomitant Timolol 0.5% (twice a day) and Dorzolamide (twice a day) or Timolol and Latanoptost (once a day) (BAK-preserved) were switched to PQ-TTFC (evening dosage). IOP, TFBUT and AEs were recorded and all patients completed the OSDI questionnaire at baseline and after 6 months. All analysis refers to right eye; left eye’s data are similar. Results:Median age was 70 [63-73] years, women were 54.9% of the sample. IOP significantly decreased (from 18 [16-21] to 15 [12-17] mmHg) after substitution (p<0,001). At baseline 31.4% of patients presented an IOP <18mmHg, the percentage increased to 80% of subjects at 6 months (p<0.001). TF-BUT improved of 2.7±1.9 sec (from 7 [5-8] to 10 [9-11] sec, p<0.001). Only one patient discontinued the new therapy due to periocular skin pigmentation. Quality of life improved from 28 (moderate) to 19 (mild) (p<0.001). Conclusions:PQ-TTFC appeared useful in this selected population: patients who underwent a regimen modification to PQ-TTFC obtained further reduction in IOP; improvement in ocular surface status with no exposition to BAK toxicity; and reported a better quality of life perception. The low discontinuation’s rate at 6 months indicates a good tolerability profile.
ARVO Annual Meeting
Orlando USA
3-8 may 2014
55
2916
2916
Rolle T; Penna R; Dallorto L; Campana F; Scudeller L; Lanteri S; Rossi G C.
File in questo prodotto:
File Dimensione Formato  
Six months study on signs and symptoms of polyquad preserved travoprost_timolol fixed combination on previously treated glaucoma patients.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 35.71 kB
Formato Adobe PDF
35.71 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/146757
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact